NCT05238870 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Fourie A, Ahtiala M, Black J, Hevia H, Coyer F, Gefen A, LeBlanc K, Smet S, Vollman K, Walsh Y, Beeckman D
Skin damage prevention in the prone ventilated critically ill patient: A comprehensive review and gap analysis (PRONEtect study). J Tissue Viability. 2021 Nov;30(4):466-477. doi: 10.1016/j.jtv.2021.09.005. Epub 2021 Sep 23. Review.

Prevention of Skin Damage in the Patient in Prone Position: Development of the "ProneTection" Education and Training Package and Study of Implementation Conditions in an Intensive Care Setting in Belgium and Sweden.

Details for clinical trial NCT05238870

Clinical trial NCT05238870 - References